CompletedPhase 2NCT02924376
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Studying Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Luis Féliz Vinas, MDIncyte Corporation
- Intervention
- Pemigatinib(drug)
- Enrollment
- 147 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2022
Study locations (30)
- Anchorage, Alaska, United States
- Phoenix, Arizona, United States
- Tempe, Arizona, United States
- Tucson, Arizona, United States
- Orange, California, United States
- San Francisco, California, United States
- Aurora, Colorado, United States
- Denver, Colorado, United States
- New Haven, Connecticut, United States
- Newark, Delaware, United States
- Washington D.C., District of Columbia, United States
- Gainesville, Florida, United States
- Miami Beach, Florida, United States
- Chicago, Illinois, United States
- Evanston, Illinois, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02924376 on ClinicalTrials.govOther trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06990659Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)University Hospital, Angers
- RECRUITINGPHASE2NCT07146646Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract CancerCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06529718Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer PatientsUNICANCER
- RECRUITINGNCT07142226Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTCCHA University
- RECRUITINGNCT07151118ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract CancerCHA University
- RECRUITINGPHASE2NCT07135544A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract CancerYongjun Chen
- RECRUITINGNCT06793709A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After ChemotherapyEisai Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06708663HX009+ IN10018 with or Without Standard Chemotherapy for Advanced Solid TumoursHangzhou Hanx Biopharmaceuticals, Ltd.
See all trials for Rare malignant epithelial tumor of liver and intrahepatic biliary tract →